Intravenous Immunoglobulin Suppresses Abortion Relates to an Increase in the CD44bright NK Subset in Recurrent Pregnancy Loss Model Mice. Issue 2 (1st August 2016)

• Record Type: Journal Article
• Authors: Tanaka, Jun; Kitashoji, Akira; Fukunaga, Yuki; Kashihara, Junichi; Nakano, Atsushi; Kamizono, Akihito
• Is Part Of: Biology of reproduction. Volume 95:Issue 2(2016)
• Publication Date: 2016-08-01
• Subjects: abortion -- IVIg -- NK cells -- recurrent pregnancy loss; Reproduction -- Periodicals; Biology; Reproduction; Reproduction; Electronic journals; Periodicals; Periodicals; 571.805
• DOI: 10.1095/biolreprod.116.138438
• Languages: English
• ISSNs: 0006-3363

Abstract

Abstract: Recurrent pregnancy loss (RPL), which mostly is of unknown etiology (unexplained RPL, uRPL), is defined as three or more consecutive spontaneous abortions. Some women with uRPL display a higher fraction and cytotoxicity of natural killer (NK) cells in the periphery and endometrium. Therefore, some uRPL cases have been explained by autoimmune abnormalities. The efficacy of intravenous immunoglobulin (IVIg) for uRPL has been confirmed in several clinical trials; however, its mechanism remains unknown, mainly because the abortion mechanism remains to be elucidated. In the present study, we analyzed the mechanisms of both abortion and IVIg action using a uRPL mouse model in which abortion was induced by lipopolysaccharide injection. IVIg attenuated the abortion rate in the uRPL model mice. The suppressive effect of IVIg was maximized by high dose administration early after lipopolysaccharide injection. Specifically, we discovered the presence of two distinct uterine NK (uNK) subsets: CD44 bright and CD44 mid . In uRPL model mice, we observed an increase in the number of CD44 bright uNK cells, while the CD44 mid uNK subset remained unchanged. Furthermore, when abortion was reduced by IVIg administration, the cell number of the CD44 bright uNK subset did not increase, which might allow differentiating pathological from normal uNK cells based on CD44 expression. Based on these results, we propose not only an effective administration protocol of IVIg to the uRPL model mice, but also a novel mechanism of abortion related to the increase in the CD44 bright subset and of IVIg, which suppresses the increase of the CD44 bright subset.